Showing 4881-4890 of 5771 results for "".
- Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-cohesive-ophthalmic-viscosurgical-device-ovd/2477174/Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new cohesive ophthalmic viscosurgical device (OVD) intended to provide surgeons with a new option in the continuum of cohesive and dispersive viscoelastics. “This is the second new OVD th
- FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)https://modernod.com/news/fda-advisory-committee-votes-unanimously-to-support-the-use-of-teprotumumab-for-the-treatment-of-thyroid-eye-disease-ted/2477171/Horizon Therapeutics announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the FDA voted unanimously that the potential benefits of teprotumumab, a fully human monoclonal antibody (mAb), outweigh the potential risks for the treatment of Thyroid Eye Disease (TED).
- Novartis Receives Positive CHMP Opinion for Beovu (Brolucizumab) for the Treatment of Wet AMDhttps://modernod.com/news/novartis-receives-positive-chmp-opinion-for-beovu-brolucizumab-for-the-treatment-of-wet-amd/2477172/Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Beovu (brolucizumab 6 mg), also known as RTH258, an investigational product for the treatment of wet age-related macular degeneration (AMD).<
- UK Regulator Unconditionally Clears Roche’s Purchase of Spark Therapeuticshttps://modernod.com/news/uk-regulator-unconditionally-clears-roches-purchase-of-spark-therapeutics/2477170/The UK Competition and Markets Authority (CMA) announced Monday the clearance of Roche’s proposed purchase of Spark Therapeutics after concluding that the deal would not negatively affect competition for haemophilia A treatments. The Swiss drugmaker noted that the offer period under the tra
- Horizon Therapeutics Trading Halted Today; FDA Committee Meeting to Discuss Teprotumumab for Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-trading-halted-today-fda-committee-meeting-to-discuss-teprotumumab-for-thyroid-eye-disease/2477167/Horizon Therapeutics announced that NASDAQ has halted trading of the company’s common stock, listed as HZNP. As per the FDA guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is holding a meeting today from 8 am to 4 pm ET to discuss
- SEED Acquires Majority Stake in Sensimedhttps://modernod.com/news/seed-acquires-majority-stake-in-sensimed/2477166/Sensimed announced the closure of a transaction whereby the Japanese public company SEED has acquired a majority stake in Sensimed. The transaction closed on November 29 with SEED now owning over 90% of outstanding sh
- FocalPoint Holdings Partners with GreenSky Patient Solutions to Enable 8,000 Ophthalmology Providers to Provide Patient Financinghttps://modernod.com/news/focalpoint-holdings-partners-with-greensky-patient-solutions-to-enable-8000-ophthalmology-providers-to-provide-patient-financing/2477162/FocalPoint Holdings announced a partnership with GreenSky Patient Solutions which enables FocalPoint Holdings’ network of 8,000 ophthalmology and optometry providers to offer flexible financing solutions, including revolving credit and installment loan products. “As the healthcare system i
- Joel Leftwich Named Executive Director of William L. Hudson BVI Workforce Innovation Centerhttps://modernod.com/news/joel-leftwich-named-executive-director-of-william-l-hudson-bvi-workforce-innovation-orkforce-innovation-center/2477155/Envision announced today that Joel Leftwich has been named executive director of the William L. Hudson BVI Workforce Innovation Center. The mission of the center, which is based out of Envision’s Wichita, Kansas headquarters, is to train and employ individuals with visual impairments, place them
- Tom Frinzi to Retire; Warren Foust Appointed President of J&J Vision Surgicalhttps://modernod.com/news/tom-frinzi-to-retire-from-johnson-replaced-by-warren-foust/2477156/Johnson & Johnson Vision announced that Warren Foust will assume the role of Worldwide President, Surgical for Johnson & Johnson Vision, effective December 2. Mr. Foust replaces Tom Frinzi, who will retire at the end of 2019 after a 35-year career in ophthalmology. Mr. Frinzi was
- ImprimisRx’s FDA-Registered Outsourcing Facility Issued California Licensehttps://modernod.com/news/imprimisrxs-fda-registered-outsourcing-facility-issued-california-license/2477158/ImprimisRx announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California. This license allows California-based ophthalmologists, optometrists, surgery centers and hospitals to order and stock I